Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Patients with Relapsed/Refractory multiple myeloma who achieved sustained minimal residual disease negativity in the dreamm-7 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

PRPaweł RobakPHPhoebe Joy HoRHRoman Hájek

Discussion

Loading...

Member takes

Overview

Phase 3 trial shows higher minimal residual disease negativity rates in multiple myeloma with dexamethasone and belantamab, suggesting improved outcomes.

Key Points

  • Sustained minimal residual disease negativity was achieved in 57% of patients with complete response in the BVd arm.
  • At the 10−5 sensitivity threshold, complete response rates were 70% in the BVd arm compared to 59% in the DVd arm.
  • Randomized trial compared bortezomib, dexamethasone, and belantamab mafodotin against daratumumab, dexamethasone, and bortezomib.
  • Results highlight the association between minimal residual disease negativity and durable responses in multiple myeloma.

Cite This Study

Robak et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df3chttps://doi.org/10.1182/blood-2025-2265
View Full Paper
Ask AI
Bookmark
Share